Inovio Pharmaceuticals

Inovio Pharmaceuticals, Inc. engages in the provision of designed DNA medicines to treat and protect people from infectious diseases, cancer, and diseases associated with human papillomavirus. Its product pipeline includes VGX-3100, INO-3107, INO-5410, INO-4800, and PENNVAX-GP. The company was founded by David B. Weiner on June 29, 1983 and is headquartered in Plymouth Meeting, PA.

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q4 2024

Inovio progresses on RRP treatment, faces trial challenges and opportunities

Inovio Pharmaceuticals is making progress on INO-3107 and other pipeline candidates while managing financials and strategic trial design.
The company faces challenges in trial design, patient representation, and regulatory requirements but sees opportunities in market access and patient outcomes.
Overall, Inovio remains focused on advancing DNA medicine and delivering on key objectives for the benefit of patients.
Analysts' questions and executive responses indicate a thorough approach to addressing concerns and ensuring trial success.

INOVIO Pharmaceuticals reports solid Q3 performance and eyes global expansion

INOVIO Pharmaceuticals showcased financial stability, regulatory progress, and scientific advancements in Q3 2024, positioning the company for future growth.
Despite financial challenges and potential hurdles, the company's strong financial position, robust pipeline, and strategic commercial planning offer opportunities for success.
Addressing challenges like financial losses, regulatory complexities, and market competitiveness will be crucial for maximizing opportunities and achieving long-term growth.
By leveraging strengths, navigating challenges, and capitalizing on opportunities, INOVIO Pharmaceuticals aims to drive innovation, secure regulatory approvals, and capture market share.

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Achieved significant progress with lead product candidate, INO-3107         Received Breakthrough Therapy designation from U.S. Food and Drug Administration (FDA) as a potential treatment for Recurrent Respiratory Papillomatosis (RRP) Received FDA feedback that data from completed Phase 1/2 trial could be used to submit a Biological License Application (BLA) under Accelerated Approval program Accelerating commercialization strategy in preparation for an earlier launch, should regulatory approval be achieved If approved, INO-3107 could revolutionize treatment options for patients with RRP, a debilitating rare disease caused by human papillomavirus (HPV) Could be first DNA medicine available in United States and first commercial product for INOVIO Continued to advance corporate strategy to align resources with focus on INO-3107 and late-stage clinical candidates closest to market, with greatest opportunity to deliver on the promise of DNA medicines for patients $167.5 million in cash, cash equivalents and short-term investments as of September 30, 2023 Investor call today at 4:30 PM ET PLYMOUTH MEETING, Pa. , Nov. 9, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results and operational highlights for the third quarter ended September 30, 2023.

INOVIO Reports Third Quarter 2023 Financial Results and Operational Highlights

PLYMOUTH MEETING, Pa. , Oct. 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that third quarter 2023 financial results will be released after the market close on November 9, 2023.

INOVIO to Report Third Quarter 2023 Financial Results on November 9, 2023

Inovio Pharma (INO) rises 19% this month after the FDA issues positive feedback on data from a phase I/II study on a rare respiratory disease candidate, INO-3107, which can be used to file a BLA.

Inovio Pharma (INO) Stock Surges 19% This Month: Here's Why

Biotechnology company Inovio saw its shares jump after the US FDA communicated that data from Inovio completed Phase 1/2 trial of INO-3107 for treating Recurrent Respiratory Papillomatosis (RRP) could support the submission of a Biological License Application (BLA) for review under the FDA's accelerated approval program. Shares of the company gained around 54% on Tuesday in midday New York trading.

Inovio shares rise after positive FDA feedback on RRP treatment candidate

Previously planned Phase 3 trial no longer required to support Biological License Application (BLA) submission If approved, INO-3107 could potentially revolutionize treatment options for patients with Recurrent Respiratory Papillomatosis (RRP), a debilitating rare disease caused by human papillomavirus (HPV) INO-3107 could be the first DNA medicine available in the United States and the first commercial product for INOVIO PLYMOUTH MEETING, Pa. , Oct. 10, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that it has received feedback from the U.S. Food and Drug Administration (FDA) that data from its completed Phase 1/2 trial of INO-3107 for the treatment of RRP could support INOVIO's submission of a BLA for review under the FDA's accelerated approval program.

INOVIO Receives FDA Feedback that Data from Completed Phase 1/2 Trial of INO-3107 Can Be Used to Submit a BLA Under Accelerated Approval Program

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) H.C. Wainwright 25th Annual Global Investment Conference Call September 12, 2023 4:30 PM ET Company Participants Jacqueline Shea - President and Chief Executive Officer Conference Call Participants Li Chen - H.C.

Inovio Pharmaceuticals, Inc. (INO) H.C. Wainwright 25th Annual Global Investment Conference (Transcript)

• Designation based on clinical evidence indicating INO-3107 may demonstrate substantial improvement over existing therapies • First Breakthrough Therapy designation for an INOVIO DNA medicine candidate PLYMOUTH MEETING, Pa. , Sept. 7, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the U.S. Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for INO-3107 as a potential treatment for patients with Recurrent Respiratory Papillomatosis (RRP).

INOVIO Announces U.S. FDA Breakthrough Therapy Designation Granted for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis

PLYMOUTH MEETING, Pa. , Aug. 29, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO will present at the H.C.

INOVIO to Present at the H.C. Wainwright 25th Annual Global Investment Conference

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.13 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.46 per share a year ago.

Inovio Pharmaceuticals (INO) Reports Q2 Loss, Tops Revenue Estimates

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q2 2023 Earnings Conference Call August 9, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Relations Jacque Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Roger Song - Jefferies Hartaj Singh - Oppenheimer Dipesh Patel - H.C. Wainwright Operator Good day, and welcome to the Inovio Second Quarter 2023 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q2 2023 Earnings Call Transcript

Preparing to initiate pivotal Phase 3 trial of INO-3107 in adult RRP patients in first quarter of 2024; INO-3107 received Orphan Drug Designation from European Commission in second quarter Scaling resources and headcount to align with strategic focus on INO-3107 and late-stage clinical candidates closest to market and with greatest opportunity to deliver on the promise of DNA medicines for patients Following biomarker analysis from REVEAL2, INOVIO is stopping investment in VGX-3100 for cervical HSIL for U.S. market; Remains committed to supporting partner ApolloBio's non-biomarker strategy for Chinese market $194.9 million in cash, cash equivalents and short-term investments at quarter end; Headcount reduction and reallocation of resources expected to lower future cash burn and  extend cash runway into third quarter of 2025 Investor call today at 4:30 PM EDT PLYMOUTH MEETING, Pa. , Aug. 9, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced its financial results for the second quarter ended June 30, 2023 and provided a strategic update.

INOVIO Announces Second Quarter 2023 Financial Results and Provides Strategic Update

PLYMOUTH MEETING, Pa. , July 26, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-associated diseases, cancer, and infectious diseases, today announced that second quarter 2023 financial results will be released after the market close on August 9, 2023.

INOVIO to Report Second Quarter 2023 Financial Results on August 9, 2023

We gave Inovalis REIT our first review in December 2022. We noted that the NAV estimates were optimistic and crystallization of that value was improbable in the short term. We review where the REIT stands after losing its largest tenant.

Inovalis: Orange You Glad You Stayed Away?

Plymouth Meeting, Pa., June 23, 2023 (GLOBE NEWSWIRE) -- INOVIO (NASDAQ:INO) has released the following pursuant to an order of the UNITED STATES DISTRICT COURT EASTERN DISTRICT OF PENNSYLVANIA:

INOVIO Announces Notice of Pendency and Proposed Settlement of Stockholder Derivative Actions

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Jefferies Healthcare Conference 2023 June 9, 2023 8:00 PM ET Company Participants Jacqueline Shea - President & CEO Michael Sumner - CMO Conference Call Participants Roger Song - Jefferies Roger Song Welcome, everyone, for last day, day three, 2023, Jeffrey's Healthcare Conference. My name is Roger Song.

Inovio Pharmaceuticals, Inc. (INO) Jefferies Healthcare Conference 2023 (Transcript)

PLYMOUTH MEETING, Pa. , May 25, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Dr. Jacqueline Shea, President and CEO, and Dr. Michael Sumner, CMO, will present at the 2023 Jefferies Healthcare Conference.

INOVIO to Present at the 2023 Jefferies Healthcare Conference

INOVIA (INO) shares surge 12% in the after-market hours, when its drug for treating a rare respiratory tract disease, INO-3107, receives orphan drug designation from the European Commission.

INOVIA's (INO) Rare Disease Drug Gets EC's Orphan Tag, Stock Up

PLYMOUTH MEETING, Pa. , May 23, 2023 /PRNewswire/ -- INOVIO (NASDAQ:INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that the European Commission (EC) has granted orphan drug designation for INO-3107, the company's product candidate for the treatment of Recurrent Respiratory Papillomatosis (RRP).

INOVIO Announces Orphan Drug Designation for INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis from the European Commission

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) 2023 RBC Capital Markets Global Healthcare Conference May 16, 2023 4:05 PM ET Company Participants Greg Renza - Biotechnology Equity Research Analyst, RBC Conference Call Participants Jacqueline Shea - President & CEO Greg Renza Great. So welcome back to the 2023 RBC Global Healthcare Conference.

Inovio Pharmaceuticals, Inc. (INO) 2023 RBC Capital Markets Global Healthcare Conference (Transcript)

Inovio (INO) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.

All You Need to Know About Inovio (INO) Rating Upgrade to Buy

Inovio Pharmaceuticals, Inc. (NASDAQ:INO ) Q1 2023 Earnings Conference Call May 10, 2023 4:30 PM ET Company Participants Thomas Hong - Manager of Investor Communications Jacqueline Shea - President and Chief Executive Officer Michael Sumner - Chief Medical Officer Peter Kies - Chief Financial Officer Conference Call Participants Hartaj Singh - Oppenheimer Li Chen - H.C. Wainwright Operator Good day and welcome to the Inovio First Quarter 2022 Financial Results Conference Call.

Inovio Pharmaceuticals, Inc. (INO) Q1 2023 Earnings Call Transcript

Inovio Pharmaceuticals (INO) came out with a quarterly loss of $0.16 per share versus the Zacks Consensus Estimate of a loss of $0.14. This compares to loss of $0.36 per share a year ago.

Inovio Pharmaceuticals (INO) Reports Q1 Loss, Misses Revenue Estimates

Announced additional positive data from Phase 1/2 trial for INO-3107 in recurrent respiratory papillomatosis patients Second cohort of trial showed 10 of the 11 (91%) patients saw a reduction in surgical interventions in the year following initial treatment New combined safety and immunological data showing tolerability and durable immune response presented at ABEA/COSM Announced positive data from Phase 1b trial with INO-4201 as an Ebola booster for ERVEBO® INO-4201 was well-tolerated and boosted humoral responses in 36 of 36 (100%) treated participants New safety and immunological data indicating potential to extend protection against Ebola presented at ECCMID Announced topline results for REVEAL2, the second Phase 3 trial for VGX-3100 as a treatment for cervical high-grade squamous intraepithelial lesions Analysis of clinical characteristics of biomarker population is ongoing; findings to be shared in third quarter 2023 Trial results achieved statistical significance in all-participants population Trial results did not meet primary endpoint in biomarker-selected population Enhanced product development team with appointment of Dr. Cheryl Elder as Senior Vice President, Regulatory Affairs Ended the first quarter 2023 with $223.8 million in cash, cash equivalents and short-term investments Company maintains cash runway projection into first quarter 2025 Management will host conference call today at 4:30 p.m. EDT PLYMOUTH MEETING, Pa.

INOVIO Reports First Quarter 2023 Financial Results and Operational Highlights

Oral presentation provided new combined safety and immunogenicity data from both cohorts (standard and side-port needles) Data indicates INO-3107 was well tolerated and has the potential to provide clinical benefit to adults with RRP PLYMOUTH MEETING, Pa. , May 8, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, presented new data from a Phase 1/2 trial of INO-3107 (NCT:04398433) for the treatment of HPV 6 and HPV 11-associated Recurrent Respiratory Papillomatosis (RRP) on May 5 th as part of the scientific program of the American Broncho-Esophagological Association (ABEA) at the Combined Otolaryngology Spring Meetings (COSM) in Boston, Massachusetts.

New Data from Phase 1/2 Trial of INO-3107 for the Treatment of Recurrent Respiratory Papillomatosis Presented at ABEA during COSM 2023

PLYMOUTH MEETING, Pa. , May 5, 2023 /PRNewswire/ -- INOVIO (NASDAQ: INO), a biotechnology company focused on developing and commercializing DNA medicines to help treat and protect people from HPV-related diseases, cancer, and infectious diseases, today announced that Jacqueline Shea, Ph.D.

News for Inovio Pharmaceuticals Stock (INO)